vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and PARKE BANCORP, INC. (PKBK). Click either name above to swap in a different company.

PARKE BANCORP, INC. is the larger business by last-quarter revenue ($22.7M vs $16.1M, roughly 1.4× Fortress Biotech, Inc.). PARKE BANCORP, INC. runs the higher net margin — 48.8% vs -24.5%, a 73.3% gap on every dollar of revenue. On growth, PARKE BANCORP, INC. posted the faster year-over-year revenue change (35.7% vs 6.3%). Over the past eight quarters, PARKE BANCORP, INC.'s revenue compounded faster (22.6% CAGR vs 11.0%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Parke Bancorp, Inc. is a U.S. regional bank holding company operating Parke Bank. It offers commercial and retail banking services including deposit products, mortgage loans, small business financing and personal lending, primarily serving customers across New Jersey and the Philadelphia metropolitan area.

FBIO vs PKBK — Head-to-Head

Bigger by revenue
PKBK
PKBK
1.4× larger
PKBK
$22.7M
$16.1M
FBIO
Growing faster (revenue YoY)
PKBK
PKBK
+29.4% gap
PKBK
35.7%
6.3%
FBIO
Higher net margin
PKBK
PKBK
73.3% more per $
PKBK
48.8%
-24.5%
FBIO
Faster 2-yr revenue CAGR
PKBK
PKBK
Annualised
PKBK
22.6%
11.0%
FBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FBIO
FBIO
PKBK
PKBK
Revenue
$16.1M
$22.7M
Net Profit
$-3.9M
$11.1M
Gross Margin
66.1%
Operating Margin
-28.8%
64.2%
Net Margin
-24.5%
48.8%
Revenue YoY
6.3%
35.7%
Net Profit YoY
41.8%
49.8%
EPS (diluted)
$-0.15
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
PKBK
PKBK
Q4 25
$16.1M
$22.7M
Q3 25
$17.6M
$21.0M
Q2 25
$16.4M
$18.7M
Q1 25
$13.1M
$17.4M
Q4 24
$15.1M
$16.8M
Q3 24
$14.6M
$15.6M
Q2 24
$14.9M
$15.5M
Q1 24
$13.0M
$15.1M
Net Profit
FBIO
FBIO
PKBK
PKBK
Q4 25
$-3.9M
$11.1M
Q3 25
$5.8M
$10.6M
Q2 25
$15.5M
$8.3M
Q1 25
$-10.6M
$7.8M
Q4 24
$-6.8M
$7.4M
Q3 24
$-12.9M
$7.5M
Q2 24
$-10.9M
$6.5M
Q1 24
$-15.4M
$6.2M
Gross Margin
FBIO
FBIO
PKBK
PKBK
Q4 25
66.1%
Q3 25
67.4%
Q2 25
69.9%
Q1 25
63.5%
Q4 24
69.1%
Q3 24
69.4%
Q2 24
61.6%
Q1 24
53.9%
Operating Margin
FBIO
FBIO
PKBK
PKBK
Q4 25
-28.8%
64.2%
Q3 25
-38.6%
64.2%
Q2 25
-222.2%
59.0%
Q1 25
-169.9%
59.1%
Q4 24
-158.3%
58.0%
Q3 24
-151.0%
60.2%
Q2 24
-186.5%
56.7%
Q1 24
-280.6%
55.4%
Net Margin
FBIO
FBIO
PKBK
PKBK
Q4 25
-24.5%
48.8%
Q3 25
33.2%
50.6%
Q2 25
94.4%
44.3%
Q1 25
-80.6%
44.6%
Q4 24
-44.7%
44.2%
Q3 24
-88.0%
48.1%
Q2 24
-73.5%
41.6%
Q1 24
-118.3%
40.7%
EPS (diluted)
FBIO
FBIO
PKBK
PKBK
Q4 25
$-0.15
$0.93
Q3 25
$0.11
$0.89
Q2 25
$0.45
$0.69
Q1 25
$-0.48
$0.65
Q4 24
$-0.16
$0.61
Q3 24
$-0.76
$0.62
Q2 24
$-0.73
$0.53
Q1 24
$-1.04
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
PKBK
PKBK
Cash + ST InvestmentsLiquidity on hand
$79.4M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$324.5M
Total Assets
$185.5M
$2.2B
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
PKBK
PKBK
Q4 25
$79.4M
Q3 25
$86.2M
Q2 25
$74.4M
Q1 25
$91.3M
Q4 24
$57.3M
Q3 24
$58.9M
Q2 24
$76.2M
Q1 24
$83.8M
Total Debt
FBIO
FBIO
PKBK
PKBK
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
FBIO
FBIO
PKBK
PKBK
Q4 25
$49.9M
$324.5M
Q3 25
$55.9M
$314.8M
Q2 25
$43.9M
$312.2M
Q1 25
$22.3M
$305.9M
Q4 24
$22.7M
$300.1M
Q3 24
$21.2M
$296.5M
Q2 24
$17.9M
$292.8M
Q1 24
$23.0M
$288.4M
Total Assets
FBIO
FBIO
PKBK
PKBK
Q4 25
$185.5M
$2.2B
Q3 25
$181.4M
$2.2B
Q2 25
$159.9M
$2.2B
Q1 25
$178.1M
$2.1B
Q4 24
$144.2M
$2.1B
Q3 24
$127.1M
$2.1B
Q2 24
$145.7M
$2.0B
Q1 24
$164.6M
$2.0B
Debt / Equity
FBIO
FBIO
PKBK
PKBK
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
PKBK
PKBK
Operating Cash FlowLast quarter
$-12.5M
$39.6M
Free Cash FlowOCF − Capex
$39.0M
FCF MarginFCF / Revenue
171.3%
Capex IntensityCapex / Revenue
2.6%
Cash ConversionOCF / Net Profit
3.57×
TTM Free Cash FlowTrailing 4 quarters
$63.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
PKBK
PKBK
Q4 25
$-12.5M
$39.6M
Q3 25
$-6.1M
$11.4M
Q2 25
$-27.6M
$6.8M
Q1 25
$-19.6M
$7.0M
Q4 24
$-12.9M
$35.2M
Q3 24
$-20.1M
$9.4M
Q2 24
$-21.8M
$8.9M
Q1 24
$-25.4M
$8.3M
Free Cash Flow
FBIO
FBIO
PKBK
PKBK
Q4 25
$39.0M
Q3 25
$11.2M
Q2 25
$6.7M
Q1 25
$6.6M
Q4 24
$35.0M
Q3 24
$9.4M
Q2 24
$8.9M
Q1 24
$8.3M
FCF Margin
FBIO
FBIO
PKBK
PKBK
Q4 25
171.3%
Q3 25
53.5%
Q2 25
35.8%
Q1 25
38.0%
Q4 24
209.1%
Q3 24
60.0%
Q2 24
57.1%
Q1 24
55.1%
Capex Intensity
FBIO
FBIO
PKBK
PKBK
Q4 25
2.6%
Q3 25
0.5%
Q2 25
0.3%
Q1 25
2.2%
Q4 24
0.7%
Q3 24
0.0%
0.1%
Q2 24
0.2%
Q1 24
0.1%
Cash Conversion
FBIO
FBIO
PKBK
PKBK
Q4 25
3.57×
Q3 25
-1.04×
1.07×
Q2 25
-1.78×
0.82×
Q1 25
0.90×
Q4 24
4.75×
Q3 24
1.25×
Q2 24
1.38×
Q1 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons